We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Myriad Genetics Inc (MYGN) Com Stk USD0.01

Sell:$25.96 Buy:$25.98 Change: $0.47 (1.77%)
NASDAQ:0.81%
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Sell:$25.96
Buy:$25.98
Change: $0.47 (1.77%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Sell:$25.96
Buy:$25.98
Change: $0.47 (1.77%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Contact details

Address:
322 North 2200 West
SALT LAKE CITY
84116
United States
Telephone:
+1 (801) 5843600
Website:
https://myriad.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MYGN
ISIN:
US62855J1043
Market cap:
$2.45 billion
Shares in issue:
90.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Paul Diaz
    President, Chief Executive Officer, Director
  • Scott Leffler
    Chief Financial Officer
  • George Daneker
    President, Chief Clinical Officer - Oncology
  • Sam Raha
    Chief Operating Officer
  • Shereen Solaiman
    Chief People Officer
  • Margaret Ancona
    Senior Vice President, Chief of Staff
  • Kevin Haas
    Chief Technology Officer
  • Dale Muzzey
    Chief Scientific Officer
  • Mark Verratti
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.